{"id":63859,"date":"2026-04-23T22:37:02","date_gmt":"2026-04-23T14:37:02","guid":{"rendered":"https:\/\/flcube.com\/?p=63859"},"modified":"2026-04-23T22:37:03","modified_gmt":"2026-04-23T14:37:03","slug":"transcenta-presents-promising-pre-clinical-data-for-proprietary-liv1-antibody-drug-conjugate-at-aacr-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63859","title":{"rendered":"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026"},"content":{"rendered":"\n<p><strong>Transcenta Holdings Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/6628:HKG\">HKG: 6628<\/a>)<\/strong> has presented <strong>pre-clinical data<\/strong> for its proprietary <strong>LIV1 antibody-drug conjugate (ADC)<\/strong> at the <strong>2026 American Association for Cancer Research (AACR) Annual Meeting<\/strong>. The data demonstrated <strong>robust antitumor activity<\/strong>, <strong>differentiated payload-dependent efficacy<\/strong>, and a <strong>favorable tolerability profile<\/strong>. LIV1, a member of the zinc transporter protein family, exhibits <strong>limited expression in normal tissues<\/strong> but is <strong>broadly and highly expressed<\/strong> in <strong>breast cancer (93%)<\/strong>, <strong>prostate cancer (72%)<\/strong>, and <strong>lung cancer (10%)<\/strong>, establishing it as a compelling cell surface target for ADC development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pre-clinical-development-summary\">Pre-clinical Development Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Transcenta Holdings Ltd (HKG: 6628)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Proprietary LIV1 antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Data Presentation<\/strong><\/td><td>2026 AACR Annual Meeting<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Pre-clinical<\/td><\/tr><tr><td><strong>Key Findings<\/strong><\/td><td>Robust antitumor activity, payload-dependent efficacy, favorable tolerability<\/td><\/tr><tr><td><strong>Target Biology<\/strong><\/td><td>LIV1 (zinc transporter protein family member)<\/td><\/tr><tr><td><strong>Tumor Expression Profile<\/strong><\/td><td>Breast cancer (93%), prostate cancer (72%), lung cancer (10%)<\/td><\/tr><tr><td><strong>Normal Tissue Expression<\/strong><\/td><td>Limited, supporting favorable therapeutic index<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-validation-amp-therapeutic-rationale\">Target Validation &amp; Therapeutic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LIV1 Biology:<\/strong> Member of the <strong>zinc transporter protein family<\/strong> with restricted expression in healthy tissues, minimizing potential on-target\/off-tumor toxicity<\/li>\n\n\n\n<li><strong>Tumor Selectivity:<\/strong> <strong>Highly overexpressed<\/strong> in major solid tumors:<\/li>\n\n\n\n<li><strong>Breast cancer:<\/strong> 93% expression rate<\/li>\n\n\n\n<li><strong>Prostate cancer:<\/strong> 72% expression rate<\/li>\n\n\n\n<li><strong>Lung cancer:<\/strong> 10% expression rate (representing significant patient population given disease prevalence)<\/li>\n\n\n\n<li><strong>ADC Platform Advantages:<\/strong> Leverages Transcenta&#8217;s proprietary antibody engineering and conjugation technologies to optimize drug-to-antibody ratio (DAR) and stability<\/li>\n\n\n\n<li><strong>Payload Differentiation:<\/strong> Demonstrated <strong>payload-dependent efficacy<\/strong>, suggesting tunable therapeutic activity based on cytotoxic warhead selection<\/li>\n\n\n\n<li><strong>Therapeutic Window:<\/strong> <strong>Favorable tolerability profile<\/strong> in pre-clinical models supports potential for higher dosing and improved efficacy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-assessment\">Market Opportunity Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Patient Population<\/th><th>Competitive Landscape<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Breast Cancer<\/strong><\/td><td>~350,000 annual cases globally with LIV1+ tumors<\/td><td>Moderate competition in ADC space; differentiated target<\/td><td>High-value indication with established ADC reimbursement<\/td><\/tr><tr><td><strong>Prostate Cancer<\/strong><\/td><td>~200,000 annual cases globally with LIV1+ tumors<\/td><td>Limited ADC options; significant unmet need<\/td><td>Emerging ADC opportunity with premium pricing potential<\/td><\/tr><tr><td><strong>Lung Cancer<\/strong><\/td><td>~250,000 annual cases globally with LIV1+ tumors<\/td><td>Highly competitive ADC market; target validation critical<\/td><td>Large addressable market despite lower expression rate<\/td><\/tr><tr><td><strong>Platform Potential<\/strong><\/td><td>Multiple additional LIV1+ tumor types under investigation<\/td><td>First-mover advantage in LIV1 targeting<\/td><td>Validates Transcenta&#8217;s target discovery capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>The presentation of robust pre-clinical data for Transcenta&#8217;s LIV1 ADC at AACR 2026 represents a significant milestone in the company&#8217;s oncology pipeline development and validates its target discovery capabilities. The <strong>high expression rates in breast and prostate cancers<\/strong>\u2014two of the most prevalent solid tumors globally\u2014provide substantial commercial opportunities, while the <strong>limited normal tissue expression<\/strong> supports an attractive safety profile.<\/p>\n\n\n\n<p>For Transcenta, this LIV1 ADC program demonstrates the company&#8217;s ability to identify and validate novel targets with strong biological rationale and commercial potential. The <strong>payload-dependent efficacy<\/strong> findings suggest sophisticated ADC engineering capabilities that could enable optimization for different tumor types or combination strategies.<\/p>\n\n\n\n<p>The timing of this data presentation is strategically significant, as the ADC market continues to expand rapidly with increasing investor and pharmaceutical partner interest in differentiated targets and platforms. Transcenta&#8217;s focus on <strong>LIV1\u2014a target with compelling tumor selectivity<\/strong>\u2014positions the company favorably for potential partnerships or out-licensing opportunities, particularly given the strong expression data in breast cancer where ADC therapies have already demonstrated substantial clinical and commercial success.<\/p>\n\n\n\n<p>The <strong>favorable tolerability profile<\/strong> is particularly noteworthy in the ADC space, where toxicity management remains a key challenge for many candidates. This safety advantage could translate into improved dosing regimens, better patient quality of life, and enhanced competitive positioning in clinical development.<\/p>\n\n\n\n<p>This pre-clinical program also reinforces Transcenta&#8217;s strategic focus on developing first-in-class or best-in-class biologics targeting validated but underexplored pathways, leveraging the company&#8217;s integrated discovery and development capabilities across its operations in China and the United States.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding pre-clinical development, target validation, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and target validation in human studies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042300072_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026042300072_c.\"><\/object><a id=\"wp-block-file--media-8966fe07-ee5d-4475-b9ae-307399253c9f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042300072_c.pdf\">2026042300072_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042300072_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8966fe07-ee5d-4475-b9ae-307399253c9f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,35,16,975,181],"class_list":["post-63859","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-adc-xdc","tag-cancer","tag-hkg-6628","tag-transcenta"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated robust antitumor activity, differentiated payload-dependent efficacy, and a favorable tolerability profile. LIV1, a member of the zinc transporter protein family, exhibits limited expression in normal tissues but is broadly and highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), establishing it as a compelling cell surface target for ADC development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63859\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026\" \/>\n<meta property=\"og:description\" content=\"Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated robust antitumor activity, differentiated payload-dependent efficacy, and a favorable tolerability profile. LIV1, a member of the zinc transporter protein family, exhibits limited expression in normal tissues but is broadly and highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), establishing it as a compelling cell surface target for ADC development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63859\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T14:37:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T14:37:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63859#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63859\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026\",\"datePublished\":\"2026-04-23T14:37:02+00:00\",\"dateModified\":\"2026-04-23T14:37:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63859\"},\"wordCount\":643,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"ADC \\\/ XDC\",\"Cancer\",\"HKG: 6628\",\"Transcenta\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63859#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63859\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63859\",\"name\":\"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-23T14:37:02+00:00\",\"dateModified\":\"2026-04-23T14:37:03+00:00\",\"description\":\"Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated robust antitumor activity, differentiated payload-dependent efficacy, and a favorable tolerability profile. LIV1, a member of the zinc transporter protein family, exhibits limited expression in normal tissues but is broadly and highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), establishing it as a compelling cell surface target for ADC development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63859#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63859\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63859#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated robust antitumor activity, differentiated payload-dependent efficacy, and a favorable tolerability profile. LIV1, a member of the zinc transporter protein family, exhibits limited expression in normal tissues but is broadly and highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), establishing it as a compelling cell surface target for ADC development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63859","og_locale":"en_US","og_type":"article","og_title":"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026","og_description":"Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated robust antitumor activity, differentiated payload-dependent efficacy, and a favorable tolerability profile. LIV1, a member of the zinc transporter protein family, exhibits limited expression in normal tissues but is broadly and highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), establishing it as a compelling cell surface target for ADC development.","og_url":"https:\/\/flcube.com\/?p=63859","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-23T14:37:02+00:00","article_modified_time":"2026-04-23T14:37:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63859#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63859"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026","datePublished":"2026-04-23T14:37:02+00:00","dateModified":"2026-04-23T14:37:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63859"},"wordCount":643,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","ADC \/ XDC","Cancer","HKG: 6628","Transcenta"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63859#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63859","url":"https:\/\/flcube.com\/?p=63859","name":"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-23T14:37:02+00:00","dateModified":"2026-04-23T14:37:03+00:00","description":"Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate (ADC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated robust antitumor activity, differentiated payload-dependent efficacy, and a favorable tolerability profile. LIV1, a member of the zinc transporter protein family, exhibits limited expression in normal tissues but is broadly and highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), establishing it as a compelling cell surface target for ADC development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63859#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63859"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63859#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63859"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63859\/revisions"}],"predecessor-version":[{"id":63862,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63859\/revisions\/63862"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}